A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World Data

NCT01381523 · clinicaltrials.gov ↗

COMPLETED

Status

1

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine Disorders

Interventions

DRUG: Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap)
DRUG: Single-entity oral triptans

Sponsor

GlaxoSmithKline